Parameters influencing renal response to SGLT2 inhibitors and GLP1 receptor agonists in type 2 diabetes patients with preserved renal function: a comparative, prospective study.
E BiancalanaG PetralliF RaggiM R DistasoG PiazzaC RossiD TricòAnna SoliniPublished in: Journal of endocrinological investigation (2022)
In our cohort, subjects with T2DM and preserved renal function show similar eGFR response to treatment with GLP1-RA or SGLT2i. Baseline urinary biomarkers or prior phenotyping do not predict treatment response. An early eGFR decline identifies patients prone to lose more eGFR over time, who may benefit more from SGLT2i treatment.
Keyphrases
- small cell lung cancer
- type diabetes
- epidermal growth factor receptor
- tyrosine kinase
- end stage renal disease
- ejection fraction
- cardiovascular disease
- newly diagnosed
- rheumatoid arthritis
- gene expression
- glycemic control
- prognostic factors
- peritoneal dialysis
- combination therapy
- patient reported outcomes
- insulin resistance
- dna methylation
- interstitial lung disease
- disease activity
- single cell
- smoking cessation